Home
CMS Biotech Pte Ltd

CMS Biotech Pte Ltd Market Share Analysis for May 2026

Finance > Investing

Domaincms.net.cn

Year Founded1995

Employees5001 - 10000

Annual Revenue> $1B

CMS Biotech Pte Ltd

CMS Biotech Pte Ltd (including company regionals)

cms.net.cn

See more website traffic and engagement information

CMS Biotech Pte Ltd Revenue up to May 2026 is > 1B

revenue generated by CMS Biotech Pte Ltd top domains

CMS Biotech Pte Ltd top domains revenue over 3 years

Revenue for CMS Biotech Pte Ltd top domains

cms.net.cn> 1B

See more with Sales Intelligence

Total visits to CMS Biotech Pte Ltd's top domains

Understand CMS Biotech Pte Ltd market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cms.net.cn5.9K

See more with Sales Intelligence

Avg. visit duration in CMS Biotech Pte Ltd's top domains

Analyze CMS Biotech Pte Ltd engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cms.net.cn00:00:04

See more with Sales Intelligence

Avg. pageviews on CMS Biotech Pte Ltd's top domains

See how CMS Biotech Pte Ltd keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cms.net.cn1.43

See more with Sales Intelligence

CMS Biotech Pte Ltd top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by CMS Biotech Pte Ltd

These are the website technologies, by industry, used by CMS Biotech Pte Ltd top domains

Mobile (2)

Meta Viewport

Content Management System (1)

WordPress

Email Services (1)

QQ Mail

Multilingual (1)

Multilingual Support

More Technologies

1

See all

News & Signals from CMS Biotech Pte Ltd

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCMS International Development And Management Limited attended event ADA Scientific Sessions on Jun 5th '26.CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions.

NewsCMS International Development And Management Limited is developing selective TYK2 inhibitor CMS-D001.China Medical System Holdings (HKEX: 0867), headquartered in Hong Kong, has received clinical trial approval from China's National Medical Products Administration (NMPA) to study its selective TYK2 inhibitor CMS-D001 in ulcerative colitis (UC) and Crohn's disease (CD), adding two inflammatory bowel disease indications to a development programme that already spans psoriasis and atopic dermatitis.